IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Composite Lymphoma
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Composite Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evorpacept M.D. Anderson Cancer Center | Phase 1/2 | CCC |
cc-5013 M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Cyclophosphamide University of Washington | Phase 1 | CC |
PREDNISONE TABLETS University of Washington | Phase 1 | CC |
Pembrolizumab University of Washington | Phase 1 | CC |
Inno-206 University of Washington | Phase 1 | CC |
VINCRISTINE SULFATE University of Washington | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →